SPG302 was well tolerated in a trial, with preliminary data supporting the idea the therapy might slow ALS progression.
Researchers developed a cell-free DNA blood test that accurately distinguishes ALS from other neurological diseases and tracks progression.
New hope could be on the horizon for ALS patients in the form of a "breakthrough" drug, researchers say. Neuvivo, a California biopharmaceutical company that develops therapies for neurodegenerative ...
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a neurodegenerative disease that affects the neurons in the brain and spinal cord. In the United States alone there are ...
Please provide your email address to receive an email when new articles are posted on . A new analysis of an overall survival study of an investigational immunotherapy platform to treat ALS found it ...
Please provide your email address to receive an email when new articles are posted on . The treatment group logged longer times to four disease-progression milestones compared with controls. At 2 ...
Amryta’s Sodesta gene therapy gains accelerated approval for ALS The Food and Drug Administration has granted accelerated ...
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurological disorder causing motor neuron death, leading to muscle ...
Two different potential biomarkers for amyotrophic lateral sclerosis (ALS) have been identified, which it's hoped will help stratify patients and guide clinical trials of new therapies. One biomarker ...
Revenue -- Reported at $3.7 million for the three months ended September 30, 2025, up from $2.3 million in the same period in 2024; the increase was due to a $1.5 million rise in license revenues, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback